Lilly’s Ebglyss Brings Once-Monthly Dosing To US Atopic Dermatitis Market
The IL-13 inhibitor will go up against Regeneron/Sanofi’s Dupixent. Lilly executives talked to Scrip about the US launch.
The IL-13 inhibitor will go up against Regeneron/Sanofi’s Dupixent. Lilly executives talked to Scrip about the US launch.